VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 18, 2014) - Vanc Pharmaceuticals Inc. ("Vanc" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF) is pleased to announce that it has received Notice of Compliance (NOC) from Health Canada for 22 generic molecules. These 22 molecules will comprise of 51 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy. The Notice of Compliance from Health Canada provides the authorization for Vanc to market and sell the generic molecules in Canada.
The current aggregate annual Canadian sales of these 22 products is estimated to be approximately $900 million.
"As Western Canada's first generic drug company we are excited to have made a significant step towards commercializing our brand in the Canadian generics market. Over the coming two quarters we plan to begin manufacturing these products and commence sales and marketing activities in Q2-2015," said Arun Nayyar, CEO of Vanc. "Our aim is to launch with additional products and we will provide further updates in the coming months."
Table 1.0 provides details on each of the molecules.
| Molecule Name | Presentations | Brand Reference | |
| 1 | VAN-Rizatriptan | 5 MG and 10 MG Tab | Maxalt™ |
| 2 | VAN-Irbesartan | 75 MG, 150 MG and 300 MG Tab | Avapro™ |
| 3 | VAN-Irbesartan-HCTZ | 150+12.5 MG, 300+12.5 MG and 300+25 MG Tab | Avalide™ |
| 4 | VAN-Donepezil | 5 MG and 10 MG Tab | Aricept™ |
| 5 | VAN-Amlodipine | 5 MG and 10 MG Tab | Norvasc™ |
| 6 | VAN-Losartan | 25 MG, 50 MG and 100 MG Tab | Cozaar™ |
| 7 | VAN-Losartan-HCTZ | 50+12.5 MG and 100+25 MG Tab | Hyzaar™ |
| 8 | VAN-Levetiracetam | 250 MG, 500 MG and 750 MG Tab | Keppra™ |
| 9 | VAN-Gabapentin | 600 MG and 800 MG Tab | Neurontin™ |
| 10 | VAN-Omeperazole | 20 MG DR Tab | Losec™ |
| 11 | VAN-Finasteride | 5 MG Tab | Proscar™ |
| 12 | VAN-Alendronate | 5 MG, 10 MG and 70 MG Tab | Fosamax™ |
| 13 | VAN-Bicalutamide | 50 MG Tab | Casodex™ |
| 14 | VAN-Letrozole | 2.5 MG Tab | Femara™ |
| 15 | VAN-Olanzapine | 2.5 MG, 5 MG, 7.5 MG, 10 MG and 15 MG Tab | Zyprexa™ |
| 16 | VAN-Sertraline cap | 25 MG, 50 MG and 100 MG Cap | Zoloft™ |
| 17 | VAN-Anastrozole | 1 MG Tab | Arimidex™ |
| 18 | VAN-Pantoprazole | 40 MG Tab | Pantoloc™ |
| 19 | VAN-Gabapentin | 100 MG, 300 MG and 400 MG Cap | Neurontin™ |
| 20 | VAN-Ciprofloxacin | 250 MG, 500 MG and 750 MG Tab | Cipro™ |
| 21 | VAN-Montelukast | 4 MG and 5 MG Chew Tabs, 10 MG Tab | Singulair™ |
| 22 | VAN-Sildenafil | 25 MG, 50 MG and 100 MG Tab | Viagra™ |
On behalf of:
Vanc Pharmaceuticals Inc.
Jamie Lewin, Director and CFO
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information:
Jamie Lewin
Director and CFO
jlewin@vancpharm.com